Parkinson's Disease Treatments
Find Parkinson's Disease Treatments
Generic Name
Pramipexole
FDA approval date: October 08, 2010
Classification: Nonergot Dopamine Agonist
Form: Tablet
What is Pramipexole?
Pramipexole dihydrochloride is a non-ergot dopamine agonist indicated for the treatment of: Parkinson’s disease .
Approved To Treat
Save this treatment for later
Not sure about your diagnosis?
Tired of the same old research?
Related Clinical Trials
Bioequivalence of Two Pramipexole Tablets Following Oral Administration in Healthy Participants (an Open-label, Randomised, Multiple-dose, Two-way Crossover Trial)
Summary: The goal of this study is to find out whether pramipexole tablets made at two different production sites are handled in the same way by the body.
A Phase I Study to Evaluate the Safety, Tolerability and Pharmacokinetics of Single Doses of KLA478 in Healthy Volunteers
Summary: The purpose of this study is to evaluate the safety and tolerability and pharmacokinetics of single doses of KLA478 in healthy volunteers；
Stratified Pharmacological Approaches for Regulating Circuit-Level Effects Study
Summary: This research study aims to understand how people with depression respond to the medication pramipexole and to determine whether clinical response differs depending on the function of specific circuits in the brain. The investigators hope to learn which circuits are involved in depression and how these circuits interact with pramipexole to affect mood, behavior, and cognition. Eligible participant...